201 related articles for article (PubMed ID: 26207369)
1. Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury.
Awad AS; You H; Gao T; Gvritishvili A; Cooper TK; Tombran-Tink J
PLoS One; 2015; 10(7):e0133777. PubMed ID: 26207369
[TBL] [Abstract][Full Text] [Related]
2. Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury.
Awad AS; Gao T; Gvritishvili A; You H; Liu Y; Cooper TK; Reeves WB; Tombran-Tink J
Am J Physiol Renal Physiol; 2013 Sep; 305(6):F891-900. PubMed ID: 23884140
[TBL] [Abstract][Full Text] [Related]
3. PEDF relieves kidney injury in type 2 diabetic nephropathy mice by reducing macrophage infiltration.
Li L; Zhang L; Chen D; Yu K; Gan H; Yang G
Endokrynol Pol; 2021; 72(6):643-651. PubMed ID: 34647607
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
[TBL] [Abstract][Full Text] [Related]
5. Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy.
You H; Gao T; Cooper TK; Morris SM; Awad AS
Am J Physiol Renal Physiol; 2015 Sep; 309(5):F447-55. PubMed ID: 26041444
[TBL] [Abstract][Full Text] [Related]
6. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
Maeda S; Matsui T; Takeuchi M; Yoshida Y; Yamakawa R; Fukami K; Yamagishi S
Pharmacol Res; 2011 Mar; 63(3):241-8. PubMed ID: 21115116
[TBL] [Abstract][Full Text] [Related]
7. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice.
Liu Y; Leo LF; McGregor C; Grivitishvili A; Barnstable CJ; Tombran-Tink J
Mol Med; 2012 Dec; 18(1):1387-401. PubMed ID: 23019073
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy.
Wang JJ; Zhang SX; Mott R; Chen Y; Knapp RR; Cao W; Ma JX
Am J Physiol Renal Physiol; 2008 May; 294(5):F1166-73. PubMed ID: 18322021
[TBL] [Abstract][Full Text] [Related]
9. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
[TBL] [Abstract][Full Text] [Related]
10. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities.
Wang JJ; Zhang SX; Mott R; Knapp RR; Cao W; Lau K; Ma JX
Diabetes; 2006 Jun; 55(6):1678-85. PubMed ID: 16731830
[TBL] [Abstract][Full Text] [Related]
11. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury.
Awad AS; Kinsey GR; Khutsishvili K; Gao T; Bolton WK; Okusa MD
Am J Physiol Renal Physiol; 2011 Dec; 301(6):F1358-66. PubMed ID: 21880831
[TBL] [Abstract][Full Text] [Related]
12. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.
Awad AS; You H; Gao T; Cooper TK; Nedospasov SA; Vacher J; Wilkinson PF; Farrell FX; Brian Reeves W
Kidney Int; 2015 Oct; 88(4):722-33. PubMed ID: 26061548
[TBL] [Abstract][Full Text] [Related]
13. Pigment epithelium-derived factor inhibits retinal microvascular dysfunction induced by 12/15-lipoxygenase-derived eicosanoids.
Ibrahim AS; Tawfik AM; Hussein KA; Elshafey S; Markand S; Rizk N; Duh EJ; Smith SB; Al-Shabrawey M
Biochim Biophys Acta; 2015 Mar; 1851(3):290-8. PubMed ID: 25562624
[TBL] [Abstract][Full Text] [Related]
14. Protective Role of PEDF-Derived Synthetic Peptide Against Experimental Diabetic Nephropathy.
Ishibashi Y; Matsui T; Taira J; Higashimoto Y; Yamagishi S
Horm Metab Res; 2016 Sep; 48(9):613-9. PubMed ID: 27214310
[TBL] [Abstract][Full Text] [Related]
15. Recovery of Corneal Sensitivity and Increase in Nerve Density and Wound Healing in Diabetic Mice After PEDF Plus DHA Treatment.
He J; Pham TL; Kakazu A; Bazan HEP
Diabetes; 2017 Sep; 66(9):2511-2520. PubMed ID: 28592408
[TBL] [Abstract][Full Text] [Related]
16. A physiological approach for treating endometriosis by recombinant pigment epithelium-derived factor (PEDF).
Chuderland D; Hasky N; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Shalgi R
Hum Reprod; 2013 Jun; 28(6):1626-34. PubMed ID: 23466670
[TBL] [Abstract][Full Text] [Related]
17. Elevated circulating pigment epithelium-derived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes.
Hui E; Yeung CY; Lee PC; Woo YC; Fong CH; Chow WS; Xu A; Lam KS
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2169-77. PubMed ID: 25166721
[TBL] [Abstract][Full Text] [Related]
18. Pigment epithelium-derived factor enhances tumor response to radiation through vasculature normalization in allografted lung cancer in mice.
Xu Z; Dong Y; Peng F; Yu Z; Zuo Y; Dai Z; Chen Y; Wang J; Hu X; Zhou Q; Ma H; Bao Y; Gao G; Chen M
Cancer Gene Ther; 2015 Mar; 22(4):181-7. PubMed ID: 25591809
[TBL] [Abstract][Full Text] [Related]
19. Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications.
Yamagishi S; Matsui T; Nakamura K; Ueda S; Noda Y; Imaizumi T
Curr Drug Targets; 2008 Nov; 9(11):1025-9. PubMed ID: 18991613
[TBL] [Abstract][Full Text] [Related]
20. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation.
Ide Y; Matsui T; Ishibashi Y; Takeuchi M; Yamagishi S
Microvasc Res; 2010 Sep; 80(2):227-32. PubMed ID: 20381502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
